Asset profile
Teclistamab
Multispecific antibody
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Phase 2 portion's primary endpoint is overall response rate (shown); interim data cutoff April 2024, before study completion. Single-arm, no comparator.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Teclistamab: this drug | Approved | Multispecific antibody | BCMA x CD3 | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| BCD-248 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| CM336 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| F182112 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| GR1803 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| TQB2934 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| YKST02 | Phase 2 | Multispecific antibody | BCMA x CD3 | ||
| REGN5459 | Phase 1/2 | Multispecific antibody | BCMA x CD3 | ||
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(39 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
November 2026 (2)
2027 (10)
January 2027 (2)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (4)
What to watch
What to watch
What to watch
What to watch
2028 (8)
February 2028 (1)
What to watch
April 2028 (2)
July 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (2)
December 2028 (1)
What to watch
2029 (7)
January 2029 (1)
What to watch
March 2029 (1)
What to watch
April 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
August 2029 (1)
What to watch
November 2029 (1)
What to watch
2030 (3)
April 2030 (1)
What to watch
July 2030 (1)
What to watch
September 2030 (1)
What to watch
2031 (4)
February 2031 (1)
What to watch
April 2031 (1)
What to watch
June 2031 (1)
What to watch
October 2031 (1)
What to watch
2032 (1)
November 2032 (1)
What to watch
2033 (1)
June 2033 (1)
What to watch
2036 (1)
December 2036 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.